Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments

Abstract

The invention relates to the field of proteins, more specifically to those proteins that are located on the surface of the cell. The invention, among other things, provides an inhibitor or pharmaceutical composition capable of inhibiting down-regulation of a cell surface receptor. The invention provides a method to control or up-regulate hormone activity by using inhibitors or reagents that modify down-regulation of a protein. The invention further provides a method to control or up-regulate protein activity wherein ligand-induced receptor uptake and / or degradation by endocytosis of a receptor is inhibited, preferably by inhibiting the ubiquitin / proteasome system.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of co-pending application Ser. No. 09 / 660,302 filed Sep. 12, 2000, U.S. Pat. No. 6,855,546 (Feb. 15, 2005), which is a continuation of PCT / NL99 / 00136, filed on Mar. 12, 1999, designating the United States of America, corresponding to PCT International Publication WO99 / 46298 (published in English on Sep. 16, 1999), the contents of all of which are incorporated herein in their entirety by this reference.TECHNICAL FIELD [0002] The invention relates to the field of regulating metabolic processes, for example, regulating availability and / or activity of proteins such as (cytosolic) transport proteins, enzymes and cytosolic or membrane-bound receptor proteins. BACKGROUND [0003] A receptor protein on the surface of a cell has a binding site with a high affinity for a particular signaling substance (a hormone, pheromone, neurotransmitter, etc.). The specific signaling substance is often referred to as the ligan...

AI Technical Summary

Benefits of technology

[0019] The invention, for example, provides a method for controlling or up-regulating the availability and / or signal transduction capability of a cell surface receptor comprising providing an inhibitor capable of inhibiting proteolytic cleavage or truncation of the receptor. The proteolytic cleavage or truncation of a receptor provides the basis for down-regulation since cleavage at either the extracellular or intracellular part of a receptor renders the receptor unavailable f or ligand interaction and / or signal transduction, thus inhibiting the proteolytic cleavage or truncation of a receptor therefor and provides a longer or more dense receptor availability at the cell surface and better signal transduction to the cell. Also, an increased transport of a transporter / receptor from the intracellular compartments to the cell-surface and / or a decreased transport of a transporter / receptor from the cell surface to intracellular compartments is now induced, whereby the average time that a transporter / receptor stays at the surface of the cell is increased.

[0024] Another inhibitor according to the invention is an inhibitor which is capable of inhibiting ligand-induced receptor uptake and / or degradation by endocytosis of the receptor, for example, an inhibitor which is capable of inhibiting ligand-induced receptor uptake and / or degradation by the ubiquitin / proteasome system. We have detected that the ubiquitin / proteasome system is involved in ligand-induced degradation of cell surface receptors. Binding of ligand to a receptor initiates signal transduction and, at the same time, the ubiquitin and / or ubiquitin / proteasome system is activated by binding to the intracellular part of the receptor which leads to endocytosis and / or proteolytic cleavage or truncation of a receptor. Inhibiting the ubiquitin / proteasome system prevents this down-regulation from happening and leads to prolonged or more intense signal transduction, thus increasing the hormonal activity independent of increased hormone concentration.

[0031] Yet another embodiment of a method provided by the invention is a method wherein up-regulation of hormone receptors is achieved via preventing ligand-induced receptor-mediated uptake and degradation by endocytosis mediated via the intracellular part of a receptor. A preferred embodiment of the invention is a method whereby the ubiquitin / proteasome system that is involved in ligand-induced degradation of a hormone receptor is inhibited. We have detected that ubiquitin conjugation and / or subsequent proteasome action (the ubiquitin / proteasome system) is involved in ligand-induced degradation of cell surface receptors. Binding of hormone initiates signal transduction and at the same time the ubiquitin / proteasome system is activated and leads to endocytosis and / or degradation of a receptor. Inhibiting the ubiquitin / proteasome system prevents this down-regulation from happening and leads to longer or higher signal transduction, thus increasing the hormonal activity independent of increased hormone concentration.

[0033] The invention provides a method for controlling or up-regulating the availability of a large variety of cell surface receptors. It has now been found that the turn-over of these receptors can be regulated by ubiquitin binding, for example, in the ubiquitin / proteasome system. Inhibiting the system prevents or retards turn-over of the receptors and may lead to longer or higher signal transduction, thus increasing the hormonal activity independent of increased hormone concentration. The invention provides a method or an inhibitor for controlling or up-regulating, for example, cell surface receptors for hormones such as thyroxine, amino acid derivatives such as epinephrine, histamine or glutamine, prostaglandins, peptide or protein hormones such as glucagon, insulin, gastrin, secretin, ACTH, LH, FSH, TSH, TRH, LHRH, vasopressin, IGF-I or II, EGF, somatotropin (growth hormone), prolactin, erythropoietin, leptin, nerve growth factor, EGF, FAS, or that are cytokines. Also, transport proteins, such as calcium-, sodium-, potassium-, chloride- and proton-channel proteins are receptors (examples are glucose transporters, CFTR, aquaporins, ENAC, see also Table 1) that can now be controlled or up-regulated by a method provided by the invention. The invention provides means and methods to control the action of the ubiquitin / proteasome system to up-regulate hormone activity by using specific inhibitors of proteasome action or by using reagents that compete for the ubiquitin / proteasome system recognition sites on a receptor or membrane channel.

Problems solved by technology

Even when ligands are circulating at a high concentration, these cannot result in sufficient activation when not enough receptors are present.

In hormonal dysfunctioning, one often attempts to achieve such up-regulation simply by treating a patient with exogenous hormones; however, as explained above, such a treatment may not be effective due to the fact that the number of available surface receptors for that hormone are too low.

Exogenous hormone therapy may then even be counterproductive because the patient becomes less susceptible to the hormone in question.

Images